Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFQ056 fixed-dose study for levodopa-induced dyskinesia in Parkinson's disease
2008-008712-98Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mavoglurant in Parkinson's disease (PD) (6 arms), sponsored by Novartis. Primary endpoint: Change from baseline to endpoint at week 12 in modified Abnormal Involuntary Movement Scale total score. Started Apr 2009; status: completed.
02
Drugs
mavoglurant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2008-008712-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008712-98.